FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

SERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025, subject to completion of tender offer and other customary conditions ...

Increased 2025 guidance with expected net revenues of $818.0 million to $843.0 million, adjusted non-GAAP EBITDA of $213.0 million to $223.0 million, and adjusted non-GAAP diluted earnings per share ...

Revenue for the three months ended June 30, 2025, totaled $10.2 million, an increase of 42%, as compared to $7.2 million for the same period of 2024. This growth was within the Company's guidance of ...

Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new ...

Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same ...

NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid-September 2025 ...

Total revenue for the quarter stood at ₹496 Cr, up 77% YoY, led by 113% growth in our CDMO segment and a 38% rise in Discovery revenues, enabled by deeper engagement with global clients.

Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second ...

J.P. Morgan, Morgan Stanley and Piper Sandler are acting as joint book-running managers for the offering. Stifel and Canaccord Genuity are acting as co-managers for the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, ...